Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wasn't there a dilution exercise performed some years ago to begin purchasing tooling etc to enable a production capability ?
Third party anecdotal video evidence ..... good enough for me!
Has this 15 September BioSpace article been posted and discussed?
https://www.biospace.com/article/anavex-s-blarcamesine-slows-cognitive-decline-in-alzheimer-s-patients/
Could be interesting.........
Strength of data should carry the day if sample size exceeds 32. Confidence levels rise when sample sizes exceed 32.
Exactly! Manufacturing capability should be in place and after a quick verification production run on the final approved product .... start the conveyor belt let the marketing begin!
Assuming that plays out, TGD is proving to be more than just an R&D guy.
What say ye George ?
Didn't TGD dilute over a year ago to fund start up manufacturing cost and begin production ramp up?
In hardware R&D there comes a time where it is necessary to shoot the engineers and move into production.
I suggest it is time to move All the Scientists, managers and bureaucrats aside and obtain approval .
Maria is focusing on Neurodegenerative diseases and JP Morgan this morning. Where is Clint?
TGD probably considers he has delivered top line results for Phase 2 RETT and PDD and my read is the results are positive but my expertise was measuring circular error of probability.
I'm not a scientist or medical research kinda guy but I did design, conduct, and prepare test reports for weapon systems awhile back. The recent corporate presentation posted at https://www.anavex.com/investor-material looks suspiciously like an executive summary of test results....just saying.
Agreed. PR prior to presentation.
Looks like Supply Chain problems are in part being exacerbated by the lack of environmentally compliant trucks operating at and around the seaports in California. Looks like a chance to approach the administration and offer a partial solution to this dilemma. Anyone have Mayor Pete's home phone number?
Agreed!
Re Production Facilitization (manufacturing, logistics, sales) wasn't an earlier dilution conducted with the expressed purpose "To fund those costs")?
Bottom Line: How does one get their hands on Anavex 2-73 to begin prophylactic dosing?
Biogen's Aduhelm continues to stumble.
https://www.investors.com/news/technology/biogen-stock-and-the-aduhelm-drama-will-it-really-treat-alzheimers/?src=A00220
Biogen's Aduhelm stumbles at the starting blocks.
https://endpts.com/major-health-systems-refuse-to-administer-aduhelm-as-top-fda-leaders-meet-behind-closed-doors-to-talk-with-payers/
It is all about Cost, Schedule, and Performance.
Amen Brothers! But keep this in mind you can be a good scientist or a good leader and business man but you can't be both. So, I'll accept the lack of professional leadership and management as long as the science is solid and proves out.
Looks like Amazon moving to an "All In" position that will likely include WPRT.
https://www.cleanenergyfuels.com/press-room/clean-energy-signs-agreement-with-amazon-for-low-and-negative-carbon-rng
mrplmer,
I've been to the research center web site and couldn't find the source info you quote. Could you please provide a link to the information?
Thanks,
Pioneer
Westport Fuel Systems Announces Next Generation HPDI Development Contract with OEM Partner.
https://finance.yahoo.com/news/westport-fuel-systems-announces-next-133000049.html
Scientists make lousey Project Managers. When held to account on issues of cost, schedule, or performance they retreat to their academic bag of excuses.
Makes sense.
This looks like basic life cycle management in developing a new solution to an established "Need".
1. The need is established.
2. Anavex R&D has proposed 2-73 as the solution.
3. Proof of performance (reliability and suitability) is being demonstrated in the trials and will be presented in a report that will allow Anavex to go into full scale production or go bust.
- Didn't TGD dilute to tool up a manufacturing capability?
It takes time to gather data and analyze.
I bet there will be no serious Merger and Acquisition activity. TGD wants to be....BP (AD, PDD, Retts, COVID, Autism, MS....!).
Sit back and enjoy the ride.
Wainwright ups price target from $3 to $5.
https://www.marketbeat.com/ratings/by-issuer/hc-wainwright-stock-recommendations/
"Alone, unarmed, and unafraid": That is the mantra of the Army OV1 Mohawk crew as they flew reconnaissance and surveillance missions at night on the borders of our nations enemies.
Emerging Data to which TGD has likely access helps inform business decisions. That is where leaks might spring. So, right now all we can do is read tea leaves and body language. Spitballing opinions right now only helps relieve anxiety.
Talon; thanks for the recap. I agree with much of what you say but what happened to the production tooling/ramp-up effort a while back that a dilution activity was intended to fund or is that being flown under the radar?
The term Line of Departure comes to mind.
When would we expect to see the split settle?
When would we expect to see the split settle?
When would we expect to see the split settle?
Roche Autism Clinical trials of Balovaptan.
Balovaptan (INN; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.[1] As of August 2019, it is in a phase III clinical trial for adults and a phase II clinical trial for children for this indication.[2] On 29 January 2018, Roche announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for balovaptan in individuals with autism spectrum disorder (ASD).[3] The FDA granted this based on the results of the adult phase II clinical trial called VANILLA (Vasopressin ANtagonist to Improve sociaL communication in Autism) study[4]. The currently-recruiting (Until March 2020) phase III adult study is called V1aduct and the currently-closed (August 2019) phase II child study is called Av1ation.[citation needed]
Has anyone heard of Anavex 2-73 being used in US IAW "Right to Try"? If so any anecdotal reports associated with its use?
https://www.australianageingagenda.com.au/2020/01/31/early-findings-of-alzheimers-drug-trial-show-promise/
Varney Reports Biogen PR states Biogen Alzheimers drug has a "Decent shot at FDA approval".
Zacks declares WPRT a Must add to an investors portfolio.
https://finance.yahoo.com/news/westport-wprt-must-add-portfolio-124612401.html